Defunct Company
Total Trials
4
As Lead Sponsor
As Collaborator
0
Total Enrollment
317
NCT02387216
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
Phase: Phase 2
Role: Lead Sponsor
Start: Feb 1, 2015
Completion: Jan 2, 2019
NCT03241810
Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer
Start: Aug 15, 2017
Completion: Nov 30, 2018
NCT04383210
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Start: Sep 29, 2020
Completion: Feb 28, 2024
NCT05980416
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Phase: Phase 1
Start: Aug 10, 2023
Completion: Jun 2, 2025